PK gene profiles across human cancers. This file contains additional text and figures that support the analyses presented in the main text. (DOCX 1543Â kb
The partition of 72 mutation and 319 expression genes in 3 phases of cancer progression. The values ...
Supplementary Methods. Additional information on gene expression analyses. (DOCX 21Â kb
Tumor vs Adjacent differentially expressed genes. The full list of 164 significant genes selected fr...
Table S1. This data file contains the full list of TCGA cases for which the TEM identified a potenti...
Figure S1. Fusions in the TCGA cohort. Figure S2. Druggable protein expression outliers using mass s...
GoF and LoF gene scores for those genes that are mutated in more than 1 % of the samples. (CSV 37.9 ...
Supplementary figures. It includes all supplementary figures except Figure S4. Figure S1. Benchmark ...
Supplementary text for estimating the sensitivity of regulatory SNPs identification. (DOCX 23Â kb
Results for actionable fusions, details on genetic complexity reduction algorithm, method descriptio...
Complete listing of results. Detailed listing of the results of discriminability and cross cancer ef...
Actionable genes. A table with details on all actionable genes analyzed. (XLSX 14 kb
Materials and methods, supplementary figures and supplementary tables. (PDF 1650 kb
Table S1. List of diseases with a significant overlap between genes differentially expressed and gen...
Table S1. DNA damage response gene variants in prostate cancer cell lines. (XLSX 16 kb
Table S3. Drug repositioning hypotheses based on the significance of the overlap between genes genet...
The partition of 72 mutation and 319 expression genes in 3 phases of cancer progression. The values ...
Supplementary Methods. Additional information on gene expression analyses. (DOCX 21Â kb
Tumor vs Adjacent differentially expressed genes. The full list of 164 significant genes selected fr...
Table S1. This data file contains the full list of TCGA cases for which the TEM identified a potenti...
Figure S1. Fusions in the TCGA cohort. Figure S2. Druggable protein expression outliers using mass s...
GoF and LoF gene scores for those genes that are mutated in more than 1 % of the samples. (CSV 37.9 ...
Supplementary figures. It includes all supplementary figures except Figure S4. Figure S1. Benchmark ...
Supplementary text for estimating the sensitivity of regulatory SNPs identification. (DOCX 23Â kb
Results for actionable fusions, details on genetic complexity reduction algorithm, method descriptio...
Complete listing of results. Detailed listing of the results of discriminability and cross cancer ef...
Actionable genes. A table with details on all actionable genes analyzed. (XLSX 14 kb
Materials and methods, supplementary figures and supplementary tables. (PDF 1650 kb
Table S1. List of diseases with a significant overlap between genes differentially expressed and gen...
Table S1. DNA damage response gene variants in prostate cancer cell lines. (XLSX 16 kb
Table S3. Drug repositioning hypotheses based on the significance of the overlap between genes genet...
The partition of 72 mutation and 319 expression genes in 3 phases of cancer progression. The values ...
Supplementary Methods. Additional information on gene expression analyses. (DOCX 21Â kb
Tumor vs Adjacent differentially expressed genes. The full list of 164 significant genes selected fr...
DOI
Add to ORKG